Here are the Form 4 insider transactions from Palomino Labs Inc (PALX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PALX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PALX filings page.
Palomino Laboratories Inc. reported that director and Secretary Richard Ogawa acquired 120,000 shares of common stock on July 31, 2026 at an implied price of $5.14 per share. The shares were issued under a Share Exchange Agreement and Plan of Reorganization, in which Ogawa exchanged 300,000 shares of Vega Links, Inc. for Palomino stock. The overall transaction delivered 4,472,000 Palomino shares to the Vega Links stockholders, who sold 100% of Vega Links’ shares. After this non‑market restructuring, Ogawa directly holds 1,882,500 PALX shares.
Palomino Laboratories Inc. director and secretary Richard Ogawa made an open-market purchase of the company’s Common Stock. He bought 12,500 shares at $4.00 per share, increasing his direct holdings to 1,762,500 shares. This filing shows a modest increase in his personal investment stake.
Palomino Laboratories Inc. director Steven Denbaars made an open-market purchase of 12,500 shares of Common Stock at $4.00 per share on April 20, 2026. After this transaction, he directly owns 1,762,500 shares of the company’s Common Stock.